SG11202006457YA - Modified orthopoxvirus vectors - Google Patents

Modified orthopoxvirus vectors

Info

Publication number
SG11202006457YA
SG11202006457YA SG11202006457YA SG11202006457YA SG11202006457YA SG 11202006457Y A SG11202006457Y A SG 11202006457YA SG 11202006457Y A SG11202006457Y A SG 11202006457YA SG 11202006457Y A SG11202006457Y A SG 11202006457YA SG 11202006457Y A SG11202006457Y A SG 11202006457YA
Authority
SG
Singapore
Prior art keywords
modified orthopoxvirus
vectors
orthopoxvirus vectors
modified
orthopoxvirus
Prior art date
Application number
SG11202006457YA
Other languages
English (en)
Inventor
John C Bell
Boeuf Fabrice Le
Michael S Huh
Matthew Y Tang
Adrian Pelin
Brian Andrew Keller
Caroline J Breitbach
Michael F Burgess
Steven H Bernstein
Original Assignee
Ottawa Hospital Res Inst
Turnstone Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ottawa Hospital Res Inst, Turnstone Biologics Corp filed Critical Ottawa Hospital Res Inst
Publication of SG11202006457YA publication Critical patent/SG11202006457YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/768Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/545IL-1
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y306/00Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01023Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1) dUTP diphosphatase (3.6.1.23)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202006457YA 2018-01-05 2019-01-04 Modified orthopoxvirus vectors SG11202006457YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862614349P 2018-01-05 2018-01-05
US201862784371P 2018-12-21 2018-12-21
PCT/CA2019/050014 WO2019134048A1 (en) 2018-01-05 2019-01-04 Modified orthopoxvirus vectors

Publications (1)

Publication Number Publication Date
SG11202006457YA true SG11202006457YA (en) 2020-08-28

Family

ID=67144045

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006457YA SG11202006457YA (en) 2018-01-05 2019-01-04 Modified orthopoxvirus vectors

Country Status (12)

Country Link
US (1) US11802292B2 (zh)
EP (1) EP3735466A4 (zh)
JP (2) JP7312412B2 (zh)
KR (1) KR20200121297A (zh)
CN (1) CN113039277A (zh)
AU (1) AU2019205036A1 (zh)
BR (1) BR112020013769A2 (zh)
CA (1) CA3122431A1 (zh)
IL (1) IL275813A (zh)
MX (1) MX2020007010A (zh)
SG (1) SG11202006457YA (zh)
WO (1) WO2019134048A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3124287A1 (en) * 2018-12-21 2020-06-25 Ottawa Hospital Research Institute Modified orthopoxvirus vectors
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
EP3935182A1 (en) * 2019-03-05 2022-01-12 Amgen Inc. Use of oncolytic viruses for the treatment of cancer
CN113840914A (zh) * 2019-05-14 2021-12-24 国立大学法人鸟取大学 诱导细胞融合的痘苗病毒及其应用
WO2021099906A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
WO2023135313A1 (en) * 2022-01-17 2023-07-20 Nouscom Ag Recombinant orthopox viral vector encoding immunostimulatory proteins for cancer treatment
WO2024130212A1 (en) 2022-12-16 2024-06-20 Turnstone Biologics Corp. Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
KR20120002613A (ko) 2002-08-12 2012-01-06 제네렉스, 인코포레이티드 폭스바이러스 및 암과 관련된 방법 및 조성물
WO2004034995A2 (en) 2002-10-15 2004-04-29 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods and reagents for inducing immunity
RU2551982C2 (ru) 2006-06-20 2015-06-10 Трансжене С.А. Способ получения поксвирусов и композиции поксвирусов
KR20080084528A (ko) 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
KR20110017431A (ko) 2008-06-10 2011-02-21 아보트 러보러터리즈 신규한 트리사이클릭 화합물
NZ716825A (en) 2013-08-22 2022-02-25 Univ Pittsburgh Commonwealth Sys Higher Education Immuno-oncolytic therapies
CA3190510A1 (en) 2014-07-16 2016-01-21 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
CN105255840A (zh) 2015-10-16 2016-01-20 西安医学院 通过去除显性表位b8r重组痘苗病毒的方法及其病毒
US20190022203A1 (en) 2016-01-11 2019-01-24 Turnstone Limited Partnership Oncolytic virus and checkpoint inhibitor combination therapy
WO2017209053A1 (ja) 2016-05-30 2017-12-07 アステラス製薬株式会社 新規な遺伝子組換えワクシニアウイルス
RU2621868C1 (ru) 2016-06-24 2017-06-07 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор"" (ФБУН ГНЦ ВБ "Вектор") Рекомбинантный штамм VACΔ6 вируса осповакцины с нарушенными генами вирулентности C3L, N1L, J2R, A35R, A56R, B8R для получения живой культуральной аттенуированной вакцины против натуральной оспы и других ортопоксвирусных инфекций человека
KR20190124750A (ko) 2017-02-28 2019-11-05 사노피 치료적 rna
SG11202000312UA (en) 2017-07-14 2020-02-27 Oncorus Inc Encapsulated polynucleotides and methods of use
CA3081436A1 (en) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
CN112313339A (zh) 2018-01-05 2021-02-02 渥太华医院研究所 修饰的牛痘载体
CA3124287A1 (en) 2018-12-21 2020-06-25 Ottawa Hospital Research Institute Modified orthopoxvirus vectors

Also Published As

Publication number Publication date
US20200392535A1 (en) 2020-12-17
US11802292B2 (en) 2023-10-31
US20240132913A1 (en) 2024-04-25
EP3735466A4 (en) 2022-01-12
BR112020013769A2 (pt) 2020-12-01
KR20200121297A (ko) 2020-10-23
CA3122431A1 (en) 2019-07-11
AU2019205036A1 (en) 2020-08-20
JP7312412B2 (ja) 2023-07-21
EP3735466A1 (en) 2020-11-11
JP2021510082A (ja) 2021-04-15
CN113039277A (zh) 2021-06-25
JP2023126868A (ja) 2023-09-12
IL275813A (en) 2020-08-31
MX2020007010A (es) 2020-12-10
WO2019134048A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
IL284188A (en) Adapted orthopoxvirus vectors
IL275833A (en) Adapted vectors of vaccinia
CA185383S (en) Casque
IL275813A (en) Adapted orthopoxvirus vectors
GB201800903D0 (en) Vectors
CA185382S (en) Casque
CA185384S (en) Casque
CA185385S (en) Casque
GB201710126D0 (en) Vectors & Methods
GB201715052D0 (en) Vectors
PL3775433T3 (pl) Układ połączeń
IL273933A (en) AAV vectors
GB2590774B (en) Vector
CA184991S (en) Uroflowmeter
IL277161A (en) Parfoxvirus vectors
CA184994S (en) Uroflowmeter
GB201806174D0 (en) Improved downlighter
GB201717524D0 (en) Vectors
PL3856814T3 (pl) Dyspersyjna substancja klejąca
IL274278A (en) vectors
GB201913974D0 (en) Vector
GB201816644D0 (en) Vectors
GB201806375D0 (en) Vectors
GB201914984D0 (en) Vector
GB201906283D0 (en) Vector